Contribution of serum lipoproteins as carriers of antitumour agent RS‐1541 (palmitoyl rhizoxin) in mice
Identifieur interne : 002C93 ( Main/Exploration ); précédent : 002C92; suivant : 002C94Contribution of serum lipoproteins as carriers of antitumour agent RS‐1541 (palmitoyl rhizoxin) in mice
Auteurs : T. Tokui [Japon] ; C. Kuroiwa [Japon] ; Y. Tokui [Japon] ; K. Sasagawa [Japon] ; K. Kawai [Japon] ; T. Kobayashi [Japon] ; T. Ikeda [Japon] ; T. Komai [Japon]Source :
- Biopharmaceutics & Drug Disposition [ 0142-2782 ] ; 1994-03.
Abstract
The tumour uptake as well as the anti‐tumour activity of RS‐1541 (palmitoyl rhizoxin), a potent antineoplastic agent, were investigated in mice bearing M5076 sarcoma. After intravenous administration, 14C‐RS‐1541 preferentially bound to the lipoproteins, to which 14C‐rhizoxin did not bind. 14C‐RS‐1541 showed persisting high concentrations of radioactivity in the plasma (T1/2α, 4·9 h). The uptake of radioactivity by the tumour was second to those by the liver and spleen, and several times greater than those by the other tissues. Selective and sustained uptake by the tumour was also demonstrated by wholebody autoradiography. A considerable amount of rhizoxin was detected only in the tumour after administration of 14C‐RS‐1541, and the area under the tissue‐concentration‐time curve (AUCt) and the mean residence time (MRT) of rhizoxin in the tumour were much higher than those after administration of 14C‐rhizoxin itself. The rhizoxin formation in the tumour was significantly reduced by chloroquine, a lysosomal enzyme inhibitor. RS‐1541 showed a higher therapeutic activity than rhizoxin. At a 4 mg kg−1 dose, the maximum growth inhibition was 92% for RS‐1541 and 41% for rhizoxin. These results indicate that RS‐1541, but not rhizoxin, is taken up by the tumour via endocytosis, most likely via the low‐density‐lipoprotein receptor, after binding to lipoproteins. Thus, RS‐1541 was considered to exhibit sustained high concentration in tumours and potent anti‐tumour activity.
Url:
DOI: 10.1002/bdd.2510150202
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000785
- to stream Istex, to step Curation: 000785
- to stream Istex, to step Checkpoint: 001A78
- to stream Main, to step Merge: 002D53
- to stream Main, to step Curation: 002C93
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Contribution of serum lipoproteins as carriers of antitumour agent RS‐1541 (palmitoyl rhizoxin) in mice</title><author><name sortKey="Tokui, T" sort="Tokui, T" uniqKey="Tokui T" first="T." last="Tokui">T. Tokui</name></author><author><name sortKey="Kuroiwa, C" sort="Kuroiwa, C" uniqKey="Kuroiwa C" first="C." last="Kuroiwa">C. Kuroiwa</name></author><author><name sortKey="Tokui, Y" sort="Tokui, Y" uniqKey="Tokui Y" first="Y." last="Tokui">Y. Tokui</name></author><author><name sortKey="Sasagawa, K" sort="Sasagawa, K" uniqKey="Sasagawa K" first="K." last="Sasagawa">K. Sasagawa</name></author><author><name sortKey="Kawai, K" sort="Kawai, K" uniqKey="Kawai K" first="K." last="Kawai">K. Kawai</name></author><author><name sortKey="Kobayashi, T" sort="Kobayashi, T" uniqKey="Kobayashi T" first="T." last="Kobayashi">T. Kobayashi</name></author><author><name sortKey="Ikeda, T" sort="Ikeda, T" uniqKey="Ikeda T" first="T." last="Ikeda">T. Ikeda</name></author><author><name sortKey="Komai, T" sort="Komai, T" uniqKey="Komai T" first="T." last="Komai">T. Komai</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3A79FD96319DBBF8FA1A81C382746BD824765982</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1002/bdd.2510150202</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-SJP0DGMD-D/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000785</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000785</idno><idno type="wicri:Area/Istex/Curation">000785</idno><idno type="wicri:Area/Istex/Checkpoint">001A78</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001A78</idno><idno type="wicri:doubleKey">0142-2782:1994:Tokui T:contribution:of:serum</idno><idno type="wicri:Area/Main/Merge">002D53</idno><idno type="wicri:Area/Main/Curation">002C93</idno><idno type="wicri:Area/Main/Exploration">002C93</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Contribution of serum lipoproteins as carriers of antitumour agent RS‐1541 (palmitoyl rhizoxin) in mice</title><author><name sortKey="Tokui, T" sort="Tokui, T" uniqKey="Tokui T" first="T." last="Tokui">T. Tokui</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Analytical and Metabolic Research Laboratories, Sankyo Co., Ltd, 1‐2‐58, Hiromachi, Shinagawa, Tokyo 140</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Kuroiwa, C" sort="Kuroiwa, C" uniqKey="Kuroiwa C" first="C." last="Kuroiwa">C. Kuroiwa</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Analytical and Metabolic Research Laboratories, Sankyo Co., Ltd, 1‐2‐58, Hiromachi, Shinagawa, Tokyo 140</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Tokui, Y" sort="Tokui, Y" uniqKey="Tokui Y" first="Y." last="Tokui">Y. Tokui</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Analytical and Metabolic Research Laboratories, Sankyo Co., Ltd, 1‐2‐58, Hiromachi, Shinagawa, Tokyo 140</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Sasagawa, K" sort="Sasagawa, K" uniqKey="Sasagawa K" first="K." last="Sasagawa">K. Sasagawa</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Bioscience Research Laboratories, Sankyo Co., Ltd, 1‐2‐58, Hiromachi, Shinagawa, Tokyo 140</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Kawai, K" sort="Kawai, K" uniqKey="Kawai K" first="K." last="Kawai">K. Kawai</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Analytical and Metabolic Research Laboratories, Sankyo Co., Ltd, 1‐2‐58, Hiromachi, Shinagawa, Tokyo 140</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Kobayashi, T" sort="Kobayashi, T" uniqKey="Kobayashi T" first="T." last="Kobayashi">T. Kobayashi</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Bioscience Research Laboratories, Sankyo Co., Ltd, 1‐2‐58, Hiromachi, Shinagawa, Tokyo 140</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Ikeda, T" sort="Ikeda, T" uniqKey="Ikeda T" first="T." last="Ikeda">T. Ikeda</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Analytical and Metabolic Research Laboratories, Sankyo Co., Ltd, 1‐2‐58, Hiromachi, Shinagawa, Tokyo 140</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Komai, T" sort="Komai, T" uniqKey="Komai T" first="T." last="Komai">T. Komai</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Research Institutes, Sankyo Co., Ltd, 1‐2‐58, Hiromachi, Shinagawa, Tokyo 140</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Biopharmaceutics & Drug Disposition</title><title level="j" type="alt">BIOPHARMACEUTICS AND DRUG DISPOSITION</title><idno type="ISSN">0142-2782</idno><idno type="eISSN">1099-081X</idno><imprint><biblScope unit="vol">15</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="93">93</biblScope><biblScope unit="page" to="107">107</biblScope><biblScope unit="page-count">15</biblScope><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>New York</pubPlace><date type="published" when="1994-03">1994-03</date></imprint><idno type="ISSN">0142-2782</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0142-2782</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The tumour uptake as well as the anti‐tumour activity of RS‐1541 (palmitoyl rhizoxin), a potent antineoplastic agent, were investigated in mice bearing M5076 sarcoma. After intravenous administration, 14C‐RS‐1541 preferentially bound to the lipoproteins, to which 14C‐rhizoxin did not bind. 14C‐RS‐1541 showed persisting high concentrations of radioactivity in the plasma (T1/2α, 4·9 h). The uptake of radioactivity by the tumour was second to those by the liver and spleen, and several times greater than those by the other tissues. Selective and sustained uptake by the tumour was also demonstrated by wholebody autoradiography. A considerable amount of rhizoxin was detected only in the tumour after administration of 14C‐RS‐1541, and the area under the tissue‐concentration‐time curve (AUCt) and the mean residence time (MRT) of rhizoxin in the tumour were much higher than those after administration of 14C‐rhizoxin itself. The rhizoxin formation in the tumour was significantly reduced by chloroquine, a lysosomal enzyme inhibitor. RS‐1541 showed a higher therapeutic activity than rhizoxin. At a 4 mg kg−1 dose, the maximum growth inhibition was 92% for RS‐1541 and 41% for rhizoxin. These results indicate that RS‐1541, but not rhizoxin, is taken up by the tumour via endocytosis, most likely via the low‐density‐lipoprotein receptor, after binding to lipoproteins. Thus, RS‐1541 was considered to exhibit sustained high concentration in tumours and potent anti‐tumour activity.</div></front></TEI><affiliations><list><country><li>Japon</li></country><region><li>Région de Kantō</li></region><settlement><li>Tokyo</li></settlement></list><tree><country name="Japon"><region name="Région de Kantō"><name sortKey="Tokui, T" sort="Tokui, T" uniqKey="Tokui T" first="T." last="Tokui">T. Tokui</name></region><name sortKey="Ikeda, T" sort="Ikeda, T" uniqKey="Ikeda T" first="T." last="Ikeda">T. Ikeda</name><name sortKey="Kawai, K" sort="Kawai, K" uniqKey="Kawai K" first="K." last="Kawai">K. Kawai</name><name sortKey="Kobayashi, T" sort="Kobayashi, T" uniqKey="Kobayashi T" first="T." last="Kobayashi">T. Kobayashi</name><name sortKey="Komai, T" sort="Komai, T" uniqKey="Komai T" first="T." last="Komai">T. Komai</name><name sortKey="Kuroiwa, C" sort="Kuroiwa, C" uniqKey="Kuroiwa C" first="C." last="Kuroiwa">C. Kuroiwa</name><name sortKey="Sasagawa, K" sort="Sasagawa, K" uniqKey="Sasagawa K" first="K." last="Sasagawa">K. Sasagawa</name><name sortKey="Tokui, Y" sort="Tokui, Y" uniqKey="Tokui Y" first="Y." last="Tokui">Y. Tokui</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:3A79FD96319DBBF8FA1A81C382746BD824765982
|texte= Contribution of serum lipoproteins as carriers of antitumour agent RS‐1541 (palmitoyl rhizoxin) in mice
}}
| This area was generated with Dilib version V0.6.33. |  |